Clofazimine for hard-to-treat NTM infections
Part of Infections clinical trials.
This program provides access to clofazimine, a medicine used to treat NTM infections that haven't responded to other treatments. It is designed for people who have run out of standard options and need another way to fight the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a confirmed NTM infection (a type of bacteria) in any part of your body.
- You have already tried other treatments that didn't work, caused side effects, or you can't take them for some reason.
- You can swallow capsules.
- If you are a man, you must use a condom during sex while on treatment and for 4 months after stopping.
- If you could become pregnant, you must have a negative pregnancy test and use highly effective birth control during treatment and for 4 months after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests a shorter treatment for drug-resistant tuberculosis (TB) using a medicine called pretomanid. It aims to see if a shorter course of treatment can effectively cure TB that doesn't respond to a standard drug called rifampicin, reducing treatment time for patients.
This trial tests a new antibiotic called contezolid for people with tuberculous meningitis, an infection of the brain lining. The goal is to see if it works well and is safe.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
Hear when a new Non-Tuberculous Mycobacterial (NTM) Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.